Carlos Buesa

Carlos Buesa is the CEO of Oryzon Genomics, a biopharmaceutical company focused on developing innovative treatments for psychiatric disorders. Under his leadership, the company has made significant strides in the research and development of new therapies, including Vafidemstat, which shows promise in managing aggression in patients with borderline personality disorder.